TNKASE DIN 02244826
Status: Marketed
Holder: HOFFMANN-LA ROCHE LIMITED
Available to quote
Health Canada record
| Active ingredient(s) | TENECTEPLASE 50 MG |
|---|
| Dosage form | Powder For Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | B01AD11 TENECTEPLASE |
|---|
| Original market date | 18-Oct-2001 |
|---|
| Current status date | 18-Oct-2001 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TENECTEPLASE
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02562804 | TNKASE | HOFFMANN-LA ROCHE LIMITED | Powder For Solution | TENECTEPLASE 25 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 2622 | 2001-10-17 | New Drug Submission (NDS) | |
Request a quote for TNKASE
How to read a Canadian DIN record